Paxlovid copycat pills put to the test – but study pulled
NCT ID NCT06397144
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Pfizer study aimed to check if new combination tablets of nirmatrelvir/ritonavir (the drug in Paxlovid) work the same as the current marketed version. About 28 healthy adults were to receive single doses of different tablet forms under fasting conditions. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nirmatrelvir/ritonavir (Paxlovid)
What this could lead to
If successful, this could show that new tablet formulations work the same as the current Paxlovid, potentially offering more manufacturing options.
What could go wrong
This trial was withdrawn before enrolling anyone, so no data will be collected. It was a small, early-phase study in healthy people, not patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.